The recent report in this journal of a decrease in [ 3 H]pirenzepine binding in Brodmann's area (BA) 24 from subjects with schizophrenia (Zavitsanou et al, 2004) adds to a growing body of evidence that implicates muscarinic receptors in the pathology of schizophrenia (Dean et al, 2003) . (Dean et al, 2002) . It is therefore intriguing to postulate that decreased [ 3 H]pirenzepine binding in the cortex from subjects with schizophrenia is reflective of widespread decreases in levels of M1 receptors. This hypothesis is supported by a study that has shown a decrease in mRNA for the M1 receptor in BA 6 from subjects with schizophrenia (Mancama et al, 2003) .
Sir
The recent report in this journal of a decrease in [ 3 H]pirenzepine binding in Brodmann's area (BA) 24 from subjects with schizophrenia (Zavitsanou et al, 2004) adds to a growing body of evidence that implicates muscarinic receptors in the pathology of schizophrenia (Dean et al, 2003) . The significance of these most recent data on [ 3 H]pirenzepine binding is that they show that changes in M1/M4 receptors have some diagnostic specificity as they are not present in bipolar disorder or major depression.
Studies of muscarinic receptors in schizophrenia have advanced to allow interpretation of [ 3 H]pirenzepine binding to go beyond simple commentary on changes in M1/M4 receptors in schizophrenia. Of significance to findings on cortical [ 3 H]pirenzepine binding are recent data showing that a decrease in binding of that radioligand in BA 9 from subjects with schizophrenia was associated with a decrease in M1, but not M4, receptor protein and mRNA (Dean et al, 2002) . It is therefore intriguing to postulate that decreased [ 3 H]pirenzepine binding in the cortex from subjects with schizophrenia is reflective of widespread decreases in levels of M1 receptors. This hypothesis is supported by a study that has shown a decrease in mRNA for the M1 receptor in BA 6 from subjects with schizophrenia (Mancama et al, 2003) .
One of the problems in post-mortem CNS studies in schizophrenia is translating findings on changes in receptor densities to functional outcomes relating to the symptoms of the disorder. In the case of the M1 receptor, it is significant that one of the prominent features of M1 receptor knockout mice is that they show abnormalities in cognitive-related behavior (Anagnostaras et al, 2003) . This suggests that the M1 receptor has a significant role in maintaining normal cognitive function; this is especially significant given that subjects with schizophrenia have cognitive deficits (Pantelis et al, 1999) and low levels of cortical M1 receptors (Dean et al, 2002) . The hypothesis that deficits in cortical M1 receptors may be related to cognitive deficits in schizophrenia has been further advanced by a recent study that showed that a C267C genotype at a A276C single-nucleotide polymorphism in the M1 receptor gene was associated with poor cognitive function in subjects with schizophrenia (Liao et al, 2003) . Importantly, the C267C genotype was not associated with either schizophrenia or the severity of positive and negative symptoms. It would therefore seem that the M1 receptor is likely to play an important role in the genesis of cognitive deficits in schizophrenia.
Radioligands specific to the M1 receptor that can be used in neuroimaging have yet to be developed. However, a decrease in [ 3 H]QNB binding to the global family of muscarinic receptors has been demonstrated in the prefrontal cortex, and other CNS regions, in drug-free subjects with schizophrenia using single photon emission tomography (Raedler et al, 2003) . These data, plus data from post-mortem studies, strongly suggest there is a decrease in M1 receptors in the frontal cortex of subjects with schizophrenia, which could result in an underactivation of cholinergic pathways in the CNS of subjects with the disorder. It therefore seems logical that activation of the muscarinic/cholinergic pathways in the CNS would be an effective approach to reversing the cognitive deficits in schizophrenia. This approach is supported by recent studies using acetylcholinesterase inhibitors to increase acetylcholine levels in the CNS that have resulted in improved cognitive function in schizophrenia (Buchanan et al, 2003) and schizotypal personality disorder (Kirrane et al, 2001) . Conversely, anticholinergic agents that block muscarinic receptors impair cognitive function in subjects with schizophrenia (Minzenberg et al, 2004) . Thus, experimental neuropsychopharmacological and basic research findings support the hypothesis that activating muscarinic receptors will be a pharmacological intervention that will alleviate some of the cognitive deficits in schizophrenia. Moreover, post-mortem and genetic studies now suggest that activat-ing the M1 receptor would be the preferred mechanism by which cognitive deficits could be reversed in schizophrenia. This hypothesis should soon be testable with the development of agonist with increasing specificity for specific members of the muscarinic receptor family (Cao et al, 2003) .
